community-acquired pneumonia

Potential for the use of macrolides in the antimicrobial therapy of severe community-acquired pneumonia in adults

This paper presents mechanism of action and antimicrobial spectrum of macrolides as well as the known acquired resistance mechanisms in the common pathogens causing community-acquired pneumonia, such as Streptococcus pneumoniae and Mycoplasma …

Safety and efficacy of nemonoxacin versus levofloxacin in the treatment of community-acquired pneumonia: results of phase III, multicenter, randomized, double-blind, active-controlled, non-inferiority trial

Objective. To evaluate the efficacy and safety of a step-down strategy from intravenous to oral nemonoxacin versus a step-down strategy from intravenous to oral levofloxacin in the treatment of patients with community-acquired pneumonia. Materials and Methods. This was a phase III randomized, controlled, double-blind, double-dummy, parallel groups (2 groups), multicenter trial to evaluate the efficacy and safety of intravenous and oral nemonoxacin at a daily dose of 500 mg versus levofloxacin (Tavanic®) at a daily dose of 500 mg in the treatment of adult patients with community-acquired pneumonia.

Etiology of community-acquired pneumonia in the military personnel

Objective. To assess the etiology of community-acquired pneumonia (CAP) in the army recruits using a polymerase chain reaction (PCR) assay. Materials and Methods. Sputum, blood, bronchoalveolar lavage samples and oropharyngeal swabs collected from 255 hospitalized army recruits with radiographically confirmed diagnosis of CAP were tested by PCR assay. The comparator group included 270 otherwise healthy recruits. Detection of Streptococcus pneumoniae, Haemophilus influenzaе, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, Legionella pneumophila, adenoviruses, Herpes simplex virus I/II, cytomegalovirus was performed by PCR using commercial AmpliSens kits and GenPak DNA PCR test.

Clinico-Economic Effectiveness of Ceftaroline Fosamil for the Treatment of Hospitalised Patients with Pneumococcal Community-Acquired Pneumonia from a Societal Perspective

Objective. Due to high activity against Streptococcus pneumoniae ceftaroline fosamil (CF) presents a good option for the treatment of adults with pneumococcal communityacquired pneumonia (PCAP) requiring parenteral antibacterial therapy. We aimed to assess cost-effectiveness of CF for the treatment of PCAP in a multi-field hospital in Russia from a societal perspective. Materials and Methods. Decision tree model based on the results of two 3rd phase clinical trials (FOCUS 1, FOCUS 2) was created to represent a standard approach to the management of hospitalised patients with PCAP and estimated outcomes including possible recurrence of infection, direct and delayed attributive mortality in case of initial therapy with CF 600 mg BID vs.

Incidence of Community-Acquired Pneumonia and Acute Otitis Media in Children 0–5 Years in Russia and Role of S. pneumoniae or H. influenzae in the Etiology of the Diseases

Objective. To estimate the incidence of communityacquired pneumonias and acute otitis media and the role of S. pneumoniae and H. influenzae in these infections in children under 5 years. Materials and Methods. Investigational program PAPIRUS (Prospective Assessment of Pneumococcal Infection in RUSsia), which included multi-center prospective epidemiological study estimating the incidence of community-acquired pneumonia (CAP) and the role of S. pneumoniae and H. influenzae in CAP and acute otitis media (AOM) in children 0-5 years of age in 3 Russian cities (Barnaul, Yekaterinburg and Murmansk) and the prospective multi-center observational cohort study evaluating the incidence of AOM in children under 5 years in the same cities had been performed during 12 months.

Short Courses of Antimicrobial Therapy: a New Treatment Paradigm for Community-Acquired Pneumonia?

Over the last years, short treatment courses for different infections, including respiratory tract infections, are increasingly more discussed. This therapeutic approach has some clear benefits: improved compliance, less frequent adverse drug …

Levofloxacin in the Treatment of Community-Acquired Pneumonia: 20-Year Successful Clinical Experience

According to international post-marketing trials, levofloxacin now belongs to the antimicrobial agents being in a great demand in clinical practice. One of the main indications for its use is community-acquired pneumonia (CAP). This review article is …

Community-Acquired Pneumonia Caused by Mycoplasma pneumoniae: Literature Review and Results of the Regional Study

The article contains modern notions of epidemiology, course, clinical and diagnostic aspects of communityacquired pneumonia caused by Mycoplasma pneumoniae, standards of its treatment and antibiotic resistance of this pathogen in the world …

Comparative Clinical and Pharmacoeconomic Analysis of Different Antimicrobial Treatment Regimens in Hospitalized Patients with Community-Acquired Pneumonia

Objective. To conduct a cost-effectiveness analysis of combination of azithromycin with b-lactams (cefotaxime, ceftriaxone or amoxicillin/clavulanic acid) vs levofloxacin in hospitalized adults with community-acquired pneumonia (CAP). Materials and Methods. We performed standard search and meta-analysis of prospective clinical trials (CT) to compare clinical success rate and tolerability of regimens of antibacterial therapy (ABT) under the investigation. Direct medical costs (DC) including cost of ABT and hospital stay were calculated from the perspective of Smolensk Regional Clinical Hospital and Central Clinical Hospital of Russian Academy of Sciences.

Questionable Efficacy of Generics in the Treatment of Severe Community-Acquired Pneumonia

The retrospective analysis of treatment of patients with severe community-acquired pneumonia has been performed. It has demonstrated that the results of therapy with generic preparations of ceftriaxone and levofloxacin were inferior to original drug …